46 related articles for article (PubMed ID: 36935920)
21. Value of lymph node ratio as a prognostic factor of recurrence in medullary thyroid cancer.
Hao W; Zhao J; Guo F; Gu P; Zhang J; Huang D; Ruan X; Zeng Y; Zheng X; Gao M
PeerJ; 2023; 11():e15025. PubMed ID: 36935920
[TBL] [Abstract][Full Text] [Related]
22. [Risk factors of recurrence or metastasis in patients with medullary thyroid carcinoma].
Guo FL; Li LJ; Ruan XH; Fu GM; Zhao JZ; Hou XK; Gao M; Zheng XQ
Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(48):3849-3855. PubMed ID: 36540922
[No Abstract] [Full Text] [Related]
23. A proposed grading scheme for predicting recurrence in medullary thyroid cancer based on the Ki67 index and metastatic lymph node ratio.
Xu P; Wu D; Liu X
Endocrine; 2023 Jul; 81(1):107-115. PubMed ID: 36823341
[TBL] [Abstract][Full Text] [Related]
24. Lymph Node Ratio as a Predictive Factor of Persistent/Recurrent Disease in Patients With Medullary Thyroid Cancer: A Single-Center Retrospective Study.
Prinzi A; Frasca F; Russo M; Le Moli R; Belfiore A; Malandrino P
Endocr Pract; 2024 Mar; 30(3):194-199. PubMed ID: 38008257
[TBL] [Abstract][Full Text] [Related]
25. Metastatic Lymph Node Ratio for Predicting Recurrence in Medullary Thyroid Cancer.
Kim J; Park J; Park H; Choi MS; Jang HW; Kim TH; Kim SW; Chung JH
Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830996
[TBL] [Abstract][Full Text] [Related]
26. Nodal disease burden and outcome of medullary thyroid carcinoma.
Moses LE; Oliver JR; Rotsides JM; Shao Q; Patel KN; Morris LGT; Givi B
Head Neck; 2021 Feb; 43(2):577-584. PubMed ID: 33107153
[TBL] [Abstract][Full Text] [Related]
27. The prognostic value of lymph node ratio in Medullary thyroid carcinoma: A multi-center study.
Rozenblat T; Hirsch D; Robenshtok E; Grozinsky-Glasberg S; Gross DJ; Mazeh H; Benbassat C; Twito O; Levy S; Mizrachi A; Shpitzer T; Bachar G
Eur J Surg Oncol; 2020 Nov; 46(11):2023-2028. PubMed ID: 32389525
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of lymph node ratio in metastatic papillary thyroid carcinoma.
Mansour J; Sagiv D; Alon E; Talmi Y
J Laryngol Otol; 2018 Jan; 132(1):8-13. PubMed ID: 29122022
[TBL] [Abstract][Full Text] [Related]
29. Ratio of positive lymph nodes: The prognostic value in stage IV thyroid cancer.
Jiang T; Huang C; Xu Y; Su Y; Zhang G; Xie L; Huang L; You S; Zha J
Oncotarget; 2017 Oct; 8(45):79462-79468. PubMed ID: 29108325
[TBL] [Abstract][Full Text] [Related]
30. Timing and extension of lymphadenectomy in medullary thyroid carcinoma: A case series from a single institution.
Polistena A; Sanguinetti A; Lucchini R; Galasse S; Monacelli M; Avenia S; Boccolini A; Johnson LB; Avenia N
Int J Surg; 2017 May; 41 Suppl 1():S70-S74. PubMed ID: 28506418
[TBL] [Abstract][Full Text] [Related]
31. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging.
Amin MB; Greene FL; Edge SB; Compton CC; Gershenwald JE; Brookland RK; Meyer L; Gress DM; Byrd DR; Winchester DP
CA Cancer J Clin; 2017 Mar; 67(2):93-99. PubMed ID: 28094848
[TBL] [Abstract][Full Text] [Related]
32. Metastatic lymph node ratio can further stratify risk for mortality in medullary thyroid cancer patients: A population-based analysis.
Qu N; Shi RL; Lu ZW; Liao T; Wen D; Sun GH; Li DS; Ji QH
Oncotarget; 2016 Oct; 7(40):65937-65945. PubMed ID: 27588396
[TBL] [Abstract][Full Text] [Related]
33. Surgery for lymph node metastases of medullary thyroid carcinoma: A review.
Jin LX; Moley JF
Cancer; 2016 Feb; 122(3):358-66. PubMed ID: 26539937
[TBL] [Abstract][Full Text] [Related]
34. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.
Wells SA; Asa SL; Dralle H; Elisei R; Evans DB; Gagel RF; Lee N; Machens A; Moley JF; Pacini F; Raue F; Frank-Raue K; Robinson B; Rosenthal MS; Santoro M; Schlumberger M; Shah M; Waguespack SG;
Thyroid; 2015 Jun; 25(6):567-610. PubMed ID: 25810047
[TBL] [Abstract][Full Text] [Related]
35. Integration of a postoperative calcitonin measurement into an anatomical staging system improves initial risk stratification in medullary thyroid cancer.
Yang JH; Lindsey SC; Camacho CP; Valente FO; Germano-Neto F; Machado AL; Mamone MC; Brodskyn F; Biscolla RP; Tuttle RM; Dias-da-Silva MR; Maciel RM
Clin Endocrinol (Oxf); 2015 Dec; 83(6):938-42. PubMed ID: 25376110
[TBL] [Abstract][Full Text] [Related]
36. Prognostic and predictive markers in medullary thyroid carcinoma.
Erovic BM; Kim D; Cassol C; Goldstein DP; Irish JC; Asa SL; Mete O
Endocr Pathol; 2012 Dec; 23(4):232-42. PubMed ID: 23150029
[TBL] [Abstract][Full Text] [Related]
37. Prognostic impact of N staging in 715 medullary thyroid cancer patients: proposal for a revised staging system.
Machens A; Dralle H
Ann Surg; 2013 Feb; 257(2):323-9. PubMed ID: 22968075
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of nodal ratio in cutaneous squamous cell carcinoma of the head and neck.
Mizrachi A; Hadar T; Rabinovics N; Shpitzer T; Guttman D; Feinmesser R; Bachar G
Eur Arch Otorhinolaryngol; 2013 Feb; 270(2):647-53. PubMed ID: 22580618
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
